DEVELOPMENT OF A BIOCOMPATIBLE PRODUCT FOR FICILI_2551 INJURY THERAPY (Q2034425): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
||
| Property / contained in NUTS | |||
| Property / contained in NUTS: Province of Trieste / rank | |||
Normal rank | |||
Revision as of 09:13, 16 September 2020
Project in Italy financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DEVELOPMENT OF A BIOCOMPATIBLE PRODUCT FOR FICILI_2551 INJURY THERAPY |
Project in Italy financed by DG Regio |
Statements
39,920.0 Euro
0 references
79,839.95 Euro
0 references
50.0 percent
0 references
10 November 2017
0 references
30 June 2021
0 references
ZETA RESEARCH S.R.L.
0 references
45°40'37.52"N, 13°45'12.31"E
0 references
IL PRESENTE PROGETTO RIGUARDA LO SVILUPPO E IL TESTO IN VITRO E IN VIVO IN MODELLI PRE-CLINICI UN PRODOTTO TERAPEUTICO INNOVATIVO BASATO SULLA COMBINAZIONE DI TRE ELEMENTI (MATRICE EXTRACELLULARE, CELLULE ENDOTELIALI E FATTORI DI CRESCITA), UTILIZZANDO IL BIOREATTORE AUTOMATIZZATO NANT 001 AL FINE DI CONSENTIRE LA STANDARDIZZAZIONE DEL PROCESSO, NONCHé LA RIDUZIONE DI TEMPI E COSTI DEL PROCESSAMENTO DELLE CELLULE ENDOTELIALI AUTOLOGHE (ISOLATE DA UNA BIOPSIA DELLO STESSO PAZIENTE IN CUI VERRAN (Italian)
0 references
THIS PROJECT CONCERNS THE DEVELOPMENT AND THE IN VITRO AND IN VIVO MODELS IN PRE-CLINICAL MODELS OF AN INNOVATIVE THERAPEUTIC PRODUCT BASED ON THE COMBINATION OF THREE ELEMENTS (EXTRACELLULAR MATRIX, ENDOTHELIAL CELLS AND GROWTH DRIVERS), USING THE AUTOMATIC NANT 001 BIOREACTOR IN ORDER TO ALLOW STANDARDISATION OF THE PROCESS, AVOIDANCE OF TIME AND COST OF THE PROCESS OF AUTOLOGOUS ENDOTHELIAL CELLS (ISOLATED BY A PATIENT BIOPSY IN THE SAME PATIENT WHERE VERRAN (English)
0 references
Identifiers
D93D19000190007
0 references